Greenberg Z, Chorev M, Muhlrad A, Shteyer A, Namdar-Attar M, Casap N, Tartakovsky A, Vidson M, Bab I
Bone Laboratory, Hebrew University of Jerusalem, Israel.
J Clin Endocrinol Metab. 1995 Aug;80(8):2330-5. doi: 10.1210/jcem.80.8.7629225.
The osteogenic growth peptide (OGP) was recently characterized in regenerating bone marrow. In experimental animals, OGP increases osteogenesis. Immunoreactive OGP (irOGP) in high abundance was demonstrated in normal animal serum mainly as an OGP-OGP-binding protein (OGPBP) complex. Here we show the presence of an OGP-OGPBP system in normal human serum. The total irOGP content, of which the bound peptide comprises at least 80-90%, ranged from 480-4460 mumol/L, several orders of magnitude higher than that of other regulatory polypeptides. The steady state/total irOGP ratio declined between 23 and 49 yr of age. The bound irOGP, purified by boiling, ultrafiltration, and hydrophobic high pressure liquid chromatography, was identical to OGP obtained previously from rat regenerating marrow and mouse stromal cell cultures in terms of its amino acid sequence, immunoreactivity, and mitogenicity. These data demonstrate the usefulness of our immunoassay to measure circulating OGP. More importantly, the identity of the human OGP with that of other species indicates the peptide's evolutionary conservation and, thus, its biological importance. The natural occurrence of OGP in man signifies its potential role in the prevention of bone loss and rescue of bone mass, especially in osteoporosis.
成骨生长肽（OGP）最近在再生骨髓中得到了表征。在实验动物中，OGP可促进骨生成。在正常动物血清中，高丰度的免疫反应性OGP（irOGP）主要以OGP-OGP结合蛋白（OGPBP）复合物的形式存在。在此，我们证明了正常人类血清中存在OGP-OGPBP系统。总irOGP含量（其中结合肽至少占80%-90%）范围为480-4460μmol/L，比其他调节多肽高出几个数量级。在23至49岁之间，稳态/总irOGP比值下降。通过煮沸、超滤和疏水高效液相色谱法纯化的结合irOGP，在氨基酸序列、免疫反应性和促有丝分裂活性方面，与先前从大鼠再生骨髓和小鼠基质细胞培养物中获得的OGP相同。这些数据证明了我们的免疫测定法在测量循环OGP方面的有效性。更重要的是，人类OGP与其他物种的OGP相同，这表明该肽具有进化保守性，因此具有生物学重要性。OGP在人体中的天然存在表明其在预防骨质流失和恢复骨量方面的潜在作用，尤其是在骨质疏松症中。
